EastWest Bioscience Inc.
EASTH.V
TSX
| 04/30/2022 | 01/31/2022 | 10/31/2021 | 07/31/2021 | 04/30/2021 | |
|---|---|---|---|---|---|
| Net Income | 108.18% | 143.28% | -89.74% | -52.52% | 52.63% |
| Total Depreciation and Amortization | -13.53% | -3.39% | -0.66% | -1.17% | -8.16% |
| Total Amortization of Deferred Charges | 43.14% | 50.54% | 69.13% | 123.08% | 208.25% |
| Total Other Non-Cash Items | -2,090.54% | -21,959.55% | 88.21% | 112.28% | -129.39% |
| Change in Net Operating Assets | 224.82% | 252.00% | 48.44% | -22.75% | -65.11% |
| Cash from Operations | 3.42% | 35.72% | -65.96% | -126.20% | -71.16% |
| Capital Expenditure | -604.76% | -7,311.11% | -7,311.11% | -733.33% | -16.67% |
| Sale of Property, Plant, and Equipment | -- | 3,442.86% | -35.92% | -65.22% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 193.68% |
| Cash from Investing | -5,080.68% | -13,972.12% | -254.04% | -67.17% | 192.24% |
| Total Debt Issued | 102.20% | -86.71% | -10.81% | 11.57% | -162.91% |
| Total Debt Repaid | -102.71% | 68.59% | 44.13% | 40.23% | 185.46% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 46,300.79% | 46,300.79% | 10,188.19% | 10,188.19% | -- |
| Cash from Financing | 1,850.69% | 1,018.99% | 440.02% | 474.33% | 23.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -459.60% | 154.09% | 13,098.31% | 1,902.07% | 89.95% |
